REMEDI4ALL ( https://remedi4all.org/), an EU-funded multi-year initiative to establish Europe's leadership in the repurposing of medicines, will create a vibrant community of practice and accessible value chain for patient-centric repurposing for any disease. The consortium of 24 leading European organisations will establish and operate a permanent European research and innovation platform comprising the complete value chain for cutting edge, patient-focused repurposing, collaborating with users to execute high potential projects at any phase of development, upskilling all stakeholder groups through a comprehensive education and training portfolio, and advancing cross-sectoral policy dialogue with all relevant stakeholders and thought leaders. The tools and processes developed assembled in REMEDI4ALL will be validated in a portfolio of 4 ambitious preclinical and clinical phase demonstrators, representing high patient need in a variety of disease areas, including oncology, rare and infectious diseases.
Working closely together with research funders and the patient community, REMEDI4ALL will engage and support a substantial user base and concomitant investments through a permanently sustainable entity, working closely with the permanent European Infrastructures and partners. The community of practice comprises leading academic and clinical facilities and infrastructures, medicines regulators, health technology assessors, public agencies and funders, small and large industry, state-of-the-art artificial intelligence and in silico tools, and a global network of collaborators for optimal knowledge exchange. REMEDI4ALL will substantially increase Europe's capacity to develop high quality repurposed medicines and implement them into market, through its complete value chain and consensus-based policy development mission.
Smart Citations